The integration of cancer biomarkers into oncology has revolutionized cancer treatment,
yielding remarkable advancements in cancer therapeutics and the prognosis of cancer …

Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly
being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have …

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly develo** a
strong evidence base for use in patients with cancer. The European Society for Medical …

Background Despite advances in early detection and therapies, cancer is still one of the
most common causes of death worldwide. Since each tumor is unique, there is a need to …

Over the past decade, various liquid biopsy techniques have emerged as viable alternatives
to the analysis of traditional tissue biopsy samples. Such surrogate 'biopsies' offer numerous …

Background The role of adjuvant chemotherapy in stage II colon cancer continues to be
debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor …

Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal causes of cancer-
related death worldwide. The treatment of HCC remains challenging and is largely …

Recent rapid biotechnological breakthroughs have led to the identification of complex and
unique molecular features that drive malignancies. Precision medicine has exploited next …

Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …

Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …